PharmaShots Weekly Snapshots (May 27 – May 31, 2024)

Share this

PharmaShots Weekly Snapshots (May 27 – May 31, 2024)

This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:


AstraZeneca & Daiichi Sankyo Report the P-III (TROPION-Lung01) Study Results of Datopotamab Deruxtecan (Dato-DXd) to Treat Advanced Non-Squamous NSCLC

Read More: AstraZeneca & Daiichi Sankyo                                                        

Novartis Highlights Results from the P-III (ALIGN) Study of Atrasentan for the Treatment of IgA Nephropathy (IgAN) at ERA 2024

Read More: Novartis                                                                                              

CG Oncology to Highlight the P-II (CORE-001) Trial Data of Cretostimogene Grenadenorepvec Plus Keytruda for Bladder Cancer at ASCO 2024

Read More: CG Oncology                                                                                        

Neuren Pharmaceuticals Reports the P-II Study Results of NNZ-2591 for Pitt Hopkins Syndrome

Read More: Neuren Pharmaceuticals                                                              

Innovent Reports the P-III (CLEAR-1) Study Data of Picankibart for Treating Plaque Psoriasis in Chinese Patients

Read More: Innovent                                                                                           

Merck Reports the Data from P-III (KEYNOTE-522) Study of Keytruda for Treating Triple Negative Breast Cancer (TNBC)

Read More: Merck                                                                                              

Johnson & Johnson Reports P-III (MDD3001) Study Data of Seltorexant for Treating Major Depressive Disorder

Read More: Johnson & Johnson                                                                         

Novartis Highlights the P-III (REMIX) Trial Data of Remibrutinib to Treat Chronic Spontaneous Urticaria at EAACI 2024

Read More: Novartis                                                                                                


Sanofi Reports the US FDA’s sBLA Acceptance of Sarclisa to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Read More: Sanofi                                                                                                      

The US FDA Accepts and Grants Priority Review to Roche’s NDA of Inavolisib for Treating Breast Cancer

Read More: Roche                                                                                        

BMS’ Opdivo Plus Cisplatin and Gemcitabine Gain EC’s Approval for Treating Urothelial Carcinoma

Read More: BMS                                                                                                        

Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Read More: Tris Pharma                                                                                           

InxMed Reveals Data from the P-Ib/II Study of Ifebemtinib Plus Garsorasib for Non-Small Cell Lung Cancer (NSCLC)

Read More: InxMed                                                                                              

BMS Reports the US FDA’s Approval of Breyanzi for Treating Mantle Cell Lymphoma

Read More: BMS                                                                                                         

Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)

Read More: Sanofi & Regeneron                                                                       

AbbVie Reports the CHMP’s Positive Opinion of Skyrizi (Risankizumab) to Treat Ulcerative Colitis

Read More: AbbVie                                                                                                

Eli Lilly Receives the US FDA’s Approval for Retevmo (Selpercatinib) to Treat Thyroid Cancer or Solid Tumors

Read More: Eli Lilly                                                                                                   


The EC Grants Approval to Celltrion’s Omlyclo (Biosimilar, Xolair)

Read More: Celltrion                                                                                                  

Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)

Read More: Fresenius                                                                                       

Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi)

Read More: Bio-Thera & STADA                                                                        


Merck Animal Health’s Innovax-ND-H5 Vaccine Gains the EC’s Marketing Authorization for Chickens

Read More: Merck Animal Health                                                                            

Elanco Reports the US FDA’s Review Completion of Bovaer to be Used Across the US Dairy Industry

Read More: Elanco                                                                                         


Oncocross and JW Pharmaceutical Expand their Partnership to Develop New Therapies Using AI in Anticancer and Regenerative Medicine

Read More: Oncocross & JW Pharmaceutical                                                   

GlycoNex and PrecisemAb Join Hands to Develop New Anti-Glycan Antibodies for Cancer Therapy

Read More: GlycoNex & PrecisemAb                                                                 


Terumo Cardiovascular Reports the US FDA’s Approval of CDI OneView Monitoring System

Read More: Terumo Cardiovascular                                                                    

The US FDA Grants Clearance to InnoVoyce’s Vylo 455nm Blue Light Laser System

Read More: InnoVoyce


Johnson & Johnson to Acquire Numab's Yellow Jersey Therapeutics for an Aggregate of ~$1.25B

Read More: Johnson & Johnson & Numab                                                         

Asahi Kasei Reports the Acquisition of Calliditas Therapeutics for an Aggregate of ~$1.11B

Read More: Asahi Kasei & Calliditas Therapeutics                                               

Merck Expands its Ophthalmologic Portfolio Through the Acquisition of EyeBio

Read More: Merck & EyeBio                                                                                


Atara Biotherapeutics Reports Preclinical Data on ATA3219 to Treat B-Cell Driven Autoimmune Diseases

Read More: Atara Biotherapeutics                                                                      

Related Post: PharmaShots Weekly Snapshots (May 20 – May 24, 2024)

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions